Présentation de l'entreprise
Quantum-Si incorporated, a life sciences company, focuses on developing proprietary universal and single-molecule detection platforms specifically applied to proteomics to facilitate next-generation protein sequencing. This operational scope places the firm squarely within the Healthcare sector, specifically targeting the Medical Devices industry, where the development of advanced instrumentation is critical for advancing biological research capabilities. The company's current scale is defined by a market capitalization of $165.33M, an annual revenue of $2.44M, and a workforce comprising 145 employees. These financial dimensions suggest a small-cap enterprise operating with a highly specialized product portfolio, where the high price-to-sales ratio relative to revenue indicates significant market expectations or capital intensity typical of early-stage biotechnology and medical device innovation.
Santé financière
The company reported a revenue of $2.44M over the trailing twelve months, while simultaneously posting a net income of $-101,339,000 and an EBITDA of $-92,594,000. The substantial negative gap between revenue and net income reveals a cost structure characterized by heavy operating expenses or significant one-time charges that far exceed the gross profits generated from sales. The free cash flow stands at $-45,797,000, indicating that the company is currently burning cash, which limits its immediate financial flexibility and reliance on external capital sources or internal reserves. Despite these operational losses, the balance sheet remains robust with cash holdings of $162.91M against total debt of $4.17M, suggesting a conservative liquidity position where cash significantly outweighs obligations. This disparity is further highlighted by a debt-to-equity ratio of 1.89, which technically indicates leverage, yet the massive cash reserve mitigates the immediate risk associated with this ratio. Liquidity is exceptionally strong, evidenced by a current ratio of 7.64, which implies the company possesses more than seven times the current assets required to cover its short-term liabilities. However, the return metrics paint a picture of significant underperformance: a return on equity of -46.5% and a return on assets of -24.6% reveal that management effectiveness is currently eroding shareholder and total capital value.
Évaluation de la valorisation
Valuation metrics present a complex picture due to the company's lack of profitability, with a trailing P/E ratio of N/A and a forward P/E of -2.07. The negative forward P/E implies that the market is pricing in future earnings potential that is currently absent, as the company is not generating positive earnings to justify a traditional multiple. The price-to-book ratio is 0.75, which indicates that the market is valuing the company at 25% below its book value, suggesting the market may be discounting the firm's assets or expecting significant future challenges. Alternative valuation metrics such as the price-to-sales ratio of 67.87 and an EV/EBITDA of -0.07 suggest that investors are relying on revenue multiples rather than earnings, which is common for development-stage companies but highlights the high valuation relative to current sales. The stock has exhibited significant volatility, trading between a 52-week high of $3.10 and a low of $0.76. Without a specific current price provided in the facts to calculate a precise percentage, the range itself demonstrates the asset's sensitivity to market conditions, with the entire spread representing a substantial swing in investor sentiment. The beta value of 3.08 confirms that the stock's price volatility is more than three times that of the broader market, making it a high-risk investment relative to the overall index.
Growth & Income
The company is experiencing a contraction in top-line performance with a revenue growth rate of -62.2% year-over-year, while earnings growth is listed as N/A due to the lack of profitable earnings history. The absence of positive earnings growth relative to the sharp decline in revenue implies that the business is struggling to maintain its revenue base or is facing significant headwinds in product adoption or market demand. As a non-dividend payer, the company offers a dividend yield of N/A and maintains a payout ratio of 0.0%, which aligns with its need to reinvest any available resources or capital into growth initiatives rather than distributing income to shareholders. This reinvestment strategy is necessitated by the negative free cash flow, meaning the company must preserve capital for R&D and operations instead of returning value through dividends. The overall growth and income profile is defined by high revenue contraction, negative earnings, and a complete absence of dividend income, reflecting the high-risk, high-reward nature of a capital-intensive medical device firm in a challenging financial phase.